Studies have shown that 90% of PDAC patients have Kirsten rat sarcoma virus (KRAS) mutations, and those mutations in KRAS genes can exert anti-apoptotic effects by inducing pro-apoptotic protein downregulation (e.g., BAX) and anti-apoptotic protein upregulation (e.g., Bcl-2) [5,6] in tumor cells. Here, KRAS is linked to neoplasm.